
Opinion|Videos|June 25, 2024
Non-adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Advertisement
Episodes in this series

- The
RENOIR trial studied the safety and efficacy of non-adjuvanted vaccine in adults aged 60 years or older. What interim results were significant from this trial leading to the indication of the vaccine for this population?- Efficacy at preventing RSV-associated lower respiratory tract infections
- Adverse effects
- Trial limitations
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5


































































































